

Appendix 7: Prevalence of chronic/long-term disorders and most common medications used at any time during pregnancy by ATC level, indication for use and region (n=9,459) ^{*†}

Prevalence of chronic/long-term disorders in pregnancy and related medication use, overall and by drug groups	REGION						Total
	Western Europe n=3,201 n (%)	Northern Europe n=2,820 n (%)	Eastern Europe n=2,342 n (%)	North America n=533 n (%)	South America n=346 n (%)	Australia n=217 n (%)	
Prevalence of hypothyroidism	130 (4.1)	118 (4.2)	105 (4.5)	22 (4.1)	11 (3.2)	6 (2.8)	392 (4.1)
Medication use for hypothyroidism, total	118 (3.7)	113 (4.0)	96 (4.1)	21 (3.9)	9 (2.6)	6 (2.8)	363 (3.8)
<i>By drug group</i>							
Thyroid hormone, levothyroxine (H03AA01)	117 (3.7)	112 (4.0)	89 (3.8)	21 (3.9)	9 (2.6)	6 (2.8)	354 (3.7)
Prevalence of asthma	163 (5.1)	193 (6.8)	58 (2.5)	43 (8.1)	12 (3.5)	24 (11.1)	493 (5.2)
Medication use for asthma, total	122 (3.8)	133 (4.7)	38 (1.6)	35 (6.6)	8 (2.3)	24 (11.1)	360 (3.8)
<i>By drug group</i>							
Inhalant selective beta-2 agonists (R03AC)	94 (2.9)	66 (2.3)	26 (1.1)	32 (6.0)	7 (2.0)	24 (11.1)	249 (2.6)
Adrenergics and other drugs for COPD (R03AK)	33 (1.0)	46 (1.6)	10 (0.4)	3 (0.6)	2 (0.6)	7 (3.2)	101 (1.1)
Inhalant glucocorticoids (R03BA)	28 (0.9)	40 (1.4)	13 (0.6)	12 (2.3)	-	4 (1.8)	97 (1.0)
Systemic selective beta-2 agonists (R03CC)	-	30 (1.1)	-	2 (0.4)	-	-	32 (0.3)
Prevalence of allergy	205 (6.4)	372 (13.2)	163 (7.0)	51 (9.6)	20 (5.8)	23 (10.6)	834 (8.8)
Medication use for allergy, total	66 (2.1)	171 (6.1)	65 (2.8)	24 (4.5)	13 (3.8)	17 (7.8)	356 (3.8)
<i>By drug group</i>							
Second generation antihistamines (R06A)	29 (0.9)	104 (3.7)	27 (1.2)	17 (3.2)	4 (1.2)	5 (2.3)	186 (2.0)
Nasal corticosteroids (R01AD)	11 (0.3)	32 (1.1)	17 (0.7)	-	-	7 (3.2)	67 (0.7)
First generation antihistamines (R06A)	13 (0.4)	29 (1.0)	10 (0.4)	9 (1.7)	6 (1.7)	4 (1.8)	71 (0.8)
Prevalence of depression	95 (3.0)	144 (5.1)	29 (1.2)	52 (9.8)	4 (1.2)	25 (11.5)	349 (3.7)
Medication use for depression, total	61 (1.9)	100 (3.5)	11 (0.5)	29 (5.4)	1 (0.3)	23 (10.6)	225 (2.4)
<i>By drug group</i>							
SSRI antidepressants (N06AB)	44 (1.4)	82 (2.9)	6 (0.3)	14 (2.6)	-	14 (6.5)	160 (1.7)
SNRIs/mianserin/trazodone/mirtazapine/bupropion	9 (0.3)	11 (0.4)	1 (0.0)	15 (2.8)	-	7 (3.2)	43 (0.5)

Prevalence of chronic/long-term disorders in pregnancy and related medication use, overall and by drug groups	REGION						Total
	Western Europe n=3,201 <i>n (%)</i>	Northern Europe n=2,820 <i>n (%)</i>	Eastern Europe n=2,342 <i>n (%)</i>	North America n=533 <i>n (%)</i>	South America n=346 <i>n (%)</i>	Australia n=217 <i>n (%)</i>	
Anxiolytics, benzodiazepine (N05BA)	6 (0.2)	2 (0.1)	5 (0.2)	-	-	1 (0.5)	14 (0.1)
Antipsychotics quetiapine/olanzapine (N05AH)	2 (0.1)	4 (0.1)	-	3 (0.6)	-	3 (1.4)	12 (0.1)
Total prevalence of any chronic/long-term disorder	617 (19.3)	831 (29.5)	576 (24.6)	154 (28.9)	51 (14.7)	72 (33.2)	2,301 (24.3)
Total medication use for any chronic/long-term disorder	462 (14.4)	593 (21.0)	322 (13.7)	119 (22.3)	38 (11.0)	70 (32.3)	1,604 (17.0)

*Countries are grouped into regions as shown in Figure 1.

†Sums of percentages do not add up to total medication use as only most common medication groups are presented. Rates do not include mineral supplements, vitamins, iron, and herbal or alternative medicine products.

Abbreviations: COPD: Chronic obstructive pulmonary disease; SSRI: Selective serotonin re-uptake inhibitors; SNRI: Serotonin–noradrenaline reuptake inhibitors.